Trial Profile
A Phase I Dose-Escalation/Dose Expansion Study Of NBTXR3 Activated By Intensity Modulated Radiation Therapy In Patients With Locally Advanced Squamous Cell Carcinoma Of The Oral Cavity Or Oropharynx
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Hafnium oxide (Primary) ; Hafnium oxide (Primary)
- Indications Carcinoma; Head and neck cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms Study 102
- Sponsors Nanobiotix
- 24 Oct 2023 Results of exploratory analysis (n=56) assessing antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival presented at the 48th European Society for Medical Oncology Congress
- 23 Oct 2023 According to a Nanobiotix Media Release, data from this study presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO).
- 23 Oct 2023 Results published in the Nanobiotix Media Release